TITLE: A Pilot Study of Rimegepant in Moderate Plaque-type Psoriasis
        Study ID: [REMOVED] 
                          Document Date:  5/10/2024
Protocol  #20-07022368  
Version  Date 5/10/24  
TITLE:  A Pilot Study  of Rimegepant  in Moderate Plaque -type  Psoriasis  
IRB Protocol #:  20-07022368  
IND/IDE  #: 152321  
Version  Date:  10 May 2024  
Funding Source(s):  Pfizer,  Inc. 
Principal Investigator:  Name.  Richard D. Granstein,  MD 
Address  WGC  9 
Telephone  (646) 962- 7546
Fax (646) 962- 0033
E-mail address  rdgranst@med.cornell.edu
Co-Investigators:  Name 
Address 
Telephone 
Fax Jennifer  Vu, PA 
WGC 9  
(646) 962- 7275
(646) 962- 0033
E-mail address  jtv4002@med.cornell.edu
Name  Morgan Lynch,  PA-C 
Address  WGC  9 
Telephone  (646) 962- 5565
Fax (646) 962- 0033
E-mail address  mol9034@med.cornell.edu
Name  Neil Sadick,  MD 
Address  911 Park Ave. New York,  NY 
Telephone  (212) 772- 7242
Fax (917) 768- 7236
E-mail address  nssderm@sadickdermatology.com
Statistician:  Medical  Monitor:  
Name  Kathy  Xi Zhou,  PhD Name  Steven Cohen , MD 
Address  402 E. 67th St., New York,  NY 10065  Address  WGC  9 
Telephone  (646) 962-8027 Telephone  (646) 962-3376
Fax (646) 962-0280 Fax (646) 962-0033
E-mail address  kaz2004@med.cornell.edu E-mail address  src4005@med.cornell.edu
P
articipating Sites:  Weill Cornell  Medicine,  Sadick  Dermatology  
Protocol  #20-07022368  
Version  Date 5/10/2024  
2   
Table  of Contents 
CONFIDENTIALITY  STATEMENT  ....................................................................................................... 5 
LIST  OF ABBREVIATIONS ................................................................................................................... 6 
1. PROTOCOL  SUMMARY  ................................................................................................................... 7 
1.1 Schema  ...................................................................................................................................... 9 
1.2 Study  Objectives  and End Points  ...................................................................................... 10 
1.2.1 Primary  Objectives  .................................................................................................... 10 
1.2.2 Secondary Objectives ............................................................................................... 10 
1.2.3 Exploratory  Objectives ............................................................................................. 10 
1.2.4 Primary  Endpoints  ..................................................................................................... 10 
1.2.5 Secondary Endpoints  ............................................................................................... 10 
2. BACKGROUND ............................................................................................................................... 11 
2.1 Disease  ................................................................................................................................... 11 
2.2 Investigational  Agent/Device,  or Surg ical Treatment/Method  ......................................... 11 
2.3 Rationale  ................................................................................................................................ 12 
2.4 Risk/Benefit  Assessment  .................................................................................................... 12 
2.4.1 Known  Potential  Risks .............................................................................................. 12 
2.4.2 Known  Potential  Benefits  ......................................................................................... 13 
2.4.3 Assessment  of Potential  Risks and Benefits  ........................................................ 13 
2.5 Correlative Studies  Background  ......................................................................................... 13 
3. STUDY  DESIGN  .............................................................................................................................. 13 
3.1 Overall Design  ....................................................................................................................... 13 
3.2 Justification  for Dose  ........................................................................................................... 14 
3.3 End of Study  Definition  ........................................................................................................ 14 
4. SUBJECT  SELECTION  .................................................................................................................. 14 
4.1 Study  Population................................................................................................................... 14 
4.2 Inclusion  Criteria  ................................................................................................................... 14 
4.3 Exclusion  Criteria  ................................................................................................................. 15 
4.4 Lifestyle Considerations ....................................................................................................... 16 
4.5 Screen  Failures  ..................................................................................................................... 16 
4.6 Strategies  for Recruitment  and Retention  ......................................................................... 16 
5. REGISTRATION  PROCEDURES  ................................................................................................... 17 
5.1 Subject  Registration  (WCM  only)  ........................................................................................ 17 
5.2 Subject  Registration  (Sub -sites)  ............................................................................................. 17 
6. STUDY  PROCEDURES ................................................................................................................... 17 
6.1 Schedule  of Assessments ................................................................................................... 17 
6.1.1 Screening  Visit  (-X days before  start  of treatment ) .............................................. 19 
6.1.2 Treatment  Phase........................................................................................................  18 
6.1.2.1  Visit  1 (baseline;  Cycle  1 Day 1) .............................................................................. 18 
6.1.2.2  Visit  2 (± X day(s)) ...................................................................................................... 20 
6.1.3 Follow -up Phase ........................................................................................................ 20 
7. STUDY  INTERVENTION  ................................................................................................................. 20 
Protocol  #20-07022368  
Version  Date 5/10/2024  
3  7.2 Availability  ............................................................................................................................. 20 
7.3 Acquisition and Accountability  .......................................................................................... 20 
7.4 Formulation,  Appearance,  Packaging,  and Labeling  ....................................................... 21 
7.5 Product  Storage  and Stability  ............................................................................................ 21 
7.6 Preparation ............................................................................................................................ 21 
7.7 Dosing and Administration  .................................................................................................  21 
7.7.1 Dosing Delays/Dose  Modifications  ......................................................................... 21 
7.8 General  Concomitant  Medication and Supportive  Care  Guidelines  .............................. 21 
7.9 Duration  of Therapy  and Criteria  for Removal  from  Study  ............................................. 23 
7.10 Duration  of Follow  Up ........................................................................................................... 22 
7.11 Measures  to Minimize  Bias:  Randomization and Blinding  ................................................ 22 
7.12 Study  Intervention/Follow -up Compliance  .......................................................................... 24 
8. STUDY INTERVENTION DISCONTINUATION AND PARTICIPANT  
DISCONTINUATION/WITHDRAWAL  ............................................................................................... 24 
8.1 Discontinuation of Study  Intervention  ............................................................................... 24 
8.2 Participant  Discontinuation/Withdrawal from the Study  ................................................. 25 
8.3 Lost  to Follow  Up ................................................................................................................. 25 
9. CORRELATIVE/SPECIAL  STUDIES .............................................................................................  26 
10. MEASUREMENT  OF EFFECT  ................................................................................................... 26 
10.1 Response Criteria  ................................................................................................................... 26 
10.2 Duration  of Response  ............................................................................................................ 26 
10.3 Progression -Free  Survival  ..................................................................................................... 26 
10.4 Other  Response  Parameters  .................................................................................................  26 
11. DATA  REPORTING  / REGULATORY  CONSIDERATIONS  ..................................................... 26 
11.1 Data  Collection  ........................................................................................................................ 26 
11.1.1  REDCap  ............................................................................................................................. 26 
11.2 Regulatory Considerations  .................................................................................................... 26 
11.2.1  Institutional  Review  Board/Ethics Committee  Approval  ............................................. 26 
11.2.2  Ethical  Conduct  of the Study  ......................................................................................... 27 
11.2.3  Informed Consent  ............................................................................................................ 28 
11.2.4  Compliance with Trial Registration and Results  Posting Requirements  ................. 28 
11.2.5  Record  Retention  ............................................................................................................. 28 
12. STATISTICAL  CONSIDERATIONS  ........................................................................................... 28 
12.1 Study  Design/ Endpoints  ........................................................................................................ 28 
12.2 Sample  Size/Accrual  Rate  ...................................................................................................... 28 
12.3 Stratification  Factors  .............................................................................................................. 29 
12.4 Analysis of Endpoints  ............................................................................................................. 29 
12.4.1  Analysis of Primary  Endpoints  ................................................................................ 29 
12.4.2  Analysis of Secondary  Endpoints  ........................................................................... 29 
12.5 Interim  Analysis  ....................................................................................................................... 30 
12.6 Reporting and Exclusions  ...................................................................................................... 30 
12.6.1  Evaluation  of Toxicity  ............................................................................................... 30 
12.6.2  Evaluation of Response  ........................................................................................... 30 
13. ADVERSE  EVENT  REPORTING  REQUIREMENTS  .................................................................. 30 
13.1 Adverse  Event  Definition ........................................................................................................ 30 
Protocol  #20-07022368  
Version  Date 5/10/2024  
4  13.1.2  Adverse  Event  Characteristics and Related Attributions  .................................... 31 
13.1.3  Recording of Adverse Events  .................................................................................. 31 
13.1.4  Reporting  of AE to WCM  IRB ................................................................................... 31 
13.1.5  Reporting Events to Participants  ............................................................................ 31 
13.1.6  Events of Special  Interest  ........................................................................................ 31 
13.1.7  Reporting  of Pregnancy  ........................................................................................... 31 
13.2 Definition  of SAE ..................................................................................................................... 32 
13.2.1  Reporting  of SAE  to IRB .......................................................................................... 32 
13.2.2  Reporting of SAE to FDA [For Protocols Where WCMC is the Sponsor - 
Investigator]  .................................................................................................................................  32 
13.2.3  Reporting of SAE to Pfizer,  Inc ................................................................................ 33 
13.3 AE/SAE  Follow  Up .................................................................................................................. 34 
13.4 Time  Period  and Frequency  for Event  Assessment  and Follow  Up .................................  34 
14. UNANTICIPATED  PROBLEMS  INVOLVING  RISKS  TO SUBJECTS  OR OTHERS  ............... 34 
14.1 Definition of Unanticipated Problems Involving Risks to Subjects or Others 
(UPIRTSO)  ........................................................................................................................................ 34 
14.1.2  Unanticipated  Problem  Reporting  .......................................................................... 35 
15. DATA  AND  SAFETY  MONITORING  PLAN (DSMP)  .................................................................. 35 
16. REFERENCES  ............................................................................................................................. 38 
Protocol  #20-07022368  
Version  Date  5/10/24  
5  
 Statement  of Compliance  
 
 
(1) [The trial will be carried  out in accordance with International  Conference on Harmonization 
Good Clinical Practice (ICH GCP) and the following  
 
 
• United States  (US) Code of  Federal  Regulations  (CFR)  applicable to clinical studies 
(45 CFR Part 46, 21 CFR Part 50, 21 CFR Part 56, 21 CFR Part 312, and/or  21 CFR 
Part 812) 
 
National Institutes of Health (NIH) -funded investigators and clinical trial site staff who are 
responsible for the conduct, management, or oversight of NIH -funded clinical trials have 
completed Human Subjects Protection and ICH GCP Training.  
 
The protocol,  informed  consent  form(s),  recruitment  materials,  and all participant  materials 
will be submitted to the Institutional Review Board (IRB) for review and approval.  
Approval of both the protocol and the consent form  must be  obtained before  any 
participant  is enrolled.  Any amendment  to the protocol  will require  review  and approval  by 
the IRB before the changes are implemented  to the study. In addition, all changes to the 
consent  form will be IRB-approved;  a determination will be made regarding whether  a new 
consent needs to be obtained from participants who provided consent, using a previously 
approved consent form.]  
 
  
 
Confidentiality  Statement  
 
This document is confidential and is to be distributed for review only to investigators, potential 
investigators, consultants, study  staff, and  applicable independent ethics  committees  or 
institutional  review  boards.  The contents  of this document  shall not be disclosed  to others  without 
written authorization from  WCM, unless dis closure on ClinicalTrials.gov is federally required.  
 
 
 
   
 
Richard D. Granstein,  M.D. – PI Date 
Protocol  #20-07022368  
Version  Date  5/10/24  
6  
  
 
List of Abbreviations  
 
 
AE Adverse Event  
CFR Code  of Federal  Regulations 
CGRP  Calcitonin  Gene -related  Peptide  
CRF Case  Report  Form  
CTSC  Clinical Translational  Science  Center  
DLQI  Dermatology  Life Quality  Index  
DSMB  Data  Safety  Monitoring  Board  
DSMP  Data  Safety  Monitoring Plan 
FDA Food  and Drug  Administration 
GCP  Good Clinical Practice  
HIPAA  Health Insurance  Portability  and Accountability  Act of 1996  
HRBFA  Human  Research  Billing Analysis  Form  
HUD  Humanitarian Use Device  
ICF Informed  Consent  Form 
IDE Investigational  Device  Exemption  
IND Investigational  New Drug 
IRB 
ODT Institutional  Review Board 
Orally  Disintegrating  Tablet  
PASI  Psoriasis  Area and Severity  Index  
PHI Protected  Health  Information 
PI Principal  Investigator  
REDCap  Research Electronic  Data  Capture  
SAE Serious  Adverse Event  
SUSAR  Suspected Unexpected Serious  Adverse  Reaction  
UIRTSO  Unanticipated  Problem  Involving  Risks to  Subjects  or Others  
WCM  Weill  Cornell  Medicine  
Protocol  #20-07022368  
Version  Date  5/10/24   
  
1. Protocol  Summary  
 
Full Title: 
Short Title: 
Clinical Phase:  
Principal Investigator: 
Study Description:  
 
   
 
Sample  Size: 
Enrollment:  
 
Study  Population:  
  
 
Enrollment  Period: 
Study Design:  A Pilot Study  of Rimegepant  in Moderate Plaque- type Psoriasis 
Rimegepant for psoriasis  
2 
 
Richard D. Granstein,  MD 
 
This proposal is for a double- blind, placebo- controlled pilot study 
examining the use of an orally administered small molecule 
competitive  inhibitor  of the calcitonin  gene- related  peptide (CGRP) 
receptor for the treatment of moderately severe plaque -type 
psoriasis.  We hypothesize that interruption of CGRP  signaling will 
prove beneficial in psoriasis.  
 
N=15  for each  of 2 cohorts.  
 
The study  will enroll  30 subjects  and we anticipate screening up to 
110 subjects.  
 
Thirty adults  with mild to moderate plaque- type psoriasis who are 
otherwise generally healthy. Subjects for the study will be 18 to 75 years of age.  
 
The enrollment  period will be approximately  3 years  1 month.  
 
This is a randomized, double- blind, placebo- controlled study of 
rimegepant 75 mg dosed every other day for the treatment of mild 
to moderate psoriasis. Subjects must have at 3%  body surface 
area involvement before entry into the study. Psoriasis Area and 
Severity  Index  (PASI)  and Investigator’s  Global  Assessment  (IGA) 
scores will be calculated and subjects will each complete the 
Dermatology Life Quality Index (DLQI) instrument as well an itch 
assessments. These assessments  will be  performed  at baseline 
and every 2 weeks in follow -up. Areas of psoriasis in each subject 
will be photographed at baseline. At the subject’s option, two very 
similar appearing lesions identified for biopsy of one on day 1 and 
the other at  the end of week  16. Patient s will also  repeat the 
DLQI at each visit. Subjects  will also  be photographed at each 
visit. Subjects willdiscontinue medications after the end of week  
16. Subjects  will be evaluated again at weeks  18 and 20. 
Subjects  who complete the  20-week  protocol  will have  the option 
of entering a 3- month, open- label extension of the study in which 
they will take 75 mg of rimegepant every  other day  for an 
additional 12 weeks. Eligible subjects have  2 weeks  past visit 11 
to enroll in the extension. For thos e rolling  over before visit 11,  
visits  11 and 12 can be combined.  They  will have  the same  7 
assessments  as in the previous  portion of the study  every  4 
8 Protocol  #20-07022368  
Version  Date  5/10/24  
 
 weeks  including  an EKG.  The inclusion and exclusion  criteria 
remain the same.  
 
 
Description  of Sites:  This will be a multi -site study  taking place  at Weill  Cornell  
Medicine/New  York-Presbyterian Hospital  and Sadick  Dermatology  
 
Study  Duration:  The projected end-date for completion of this study  is 
approximately  47 months  from initiation.  
 
Participant  Duration:  Each  individual  participant  will be in  the study  for approximately  20 
weeks.  If participating in optional  extension,  they will be in the study  for an 
additional 12 weeks for a total of up to 32 weeks.  
 
Study  Agent/Device  Name  
Intervention  Description:  Rimegepant  75 mg (or placebo)  taken orally  every  other  day for 
16 weeks.  If a subject  enters  the extension  phase,  that subject  will take 
rimegepant 75 mg every other day for an additional 12 weeks.  
Primary  Objective:  
• To determine whether  rimegepant,  an orally  available competitive  inhibitor  of the CGRP 
receptor, results in improvement in psoriasis compared to placebo as assessed by the 
PASI instrument. 
 
Secondary Objectives:  
 
• To determine if the degree  of improvement  in subjects  given rimegepant  is at least  50% 
compared to the placebo group as assessed by the PASI instrument.  
 
• To determine whether  rimegepant  significantly improves  psoriasis  compared to placebo 
as assessed by the Investigator’s Global Assessment (IGA) instrument.  
 
• To determine whether  rimegepant  significantly  improves  quality  of life as assessed  by 
the Dermatology Quality of Life Index (DQLI) as compared to placebo for subjects with 
psoriasis.  
 
• To determine  whether  rimegepant  significantly  improves  the degree of itching (itch 
score) for patients with psoriasis as compared to placebo.  
 
Primary  Endpoints:  
 
1. PASI  instrument  score  
Assessments  will be made  at baseline and every  2 weeks  for 20 weeks.  
 
Secondary Endpoints:  
 
1. Fifty percent  improvement in PASI  instrument.  
2. IGA instrument score.  
3. DLQI instrument score.  
4. Itch Score.  
9  
 Protocol  
#20-07022368 Version 
Date 5/10/24 
 
1.1 Schema  
 
 
Prior to 
Enrollment  
 
 
 
    
Visit 1 
Day 0 
 
Visits  2-8 
(2 week  intervals)  
Days  14-98 
 
Visit 9 
Day 112 
 
 
 
Visit 10 
Day 126 
 
 
Visit 11* 
Day 140 
 
 
 
 
 
Extension 
Visit 11*/12  
 
 
 
Extension 
Visits  13-15 
15 participants  
 15 participants  
Perform  PASI,  IGA, DLQI,  biopsy,  and itch assessments.  
Photography  of areas  of psoriasis.  
Take history  of any adverse effects  and other  relevant  history.  
Dispense 30 tablets  of rimegepant or  placebo  tablets.  Subjects receiving ODT of 
rimegepant will be given 32 ODTs of rimegepant or 32 placebo ODTs .  
Perform  PASI,  IGA, DLQI  and itch assessments.  
Photography  of areas  of psoriasis.  
Take history of  any adverse effects  and other  relevant  history.  
Discontinue medications as  of this day. 
 
Final  Assessments  
Perform PASI,  IGA, DLQI  and itchassessments.  
Photography  of areas  of psoriasis.  
Take history of any adverse effects  andother  relevant 
history.  
Obtain history,  perform  PASI,  IGA, DLQI,  EKG,  itch assessments  and photography.  
Dispense  medications  on Visits  12 and 14. 
Stop medications  Visit 15. Obtain  informed consent.  Screen  potential  participants  by inclusion  and exclusion  criteria; 
obtain history, perform  PASI, IGA, DLQI, EKG, itch assessments  and photography.  Perform  PASI,  IGA, DLQI  and itch  assessments.  
Photography  of areas  of psoriasis.  
Take history  of any adverse  effects  and other  relevant  history.  Perform  PASI,  IGA, DLQI  and itch assessments.  
Photography  of areas  of psoriasis.  
Take history  of any adverse  effects  and other  relevant  history.  
Dispense  30 tablets  of rimegepant  or placebo tablets  (Day  56 only).  Subjects receiving ODT of rimegepant will be 
given 32 ODTs of rimegepant or 32 placebo ODTs .  
Protocol  #20-07022368  
Version  Date 5/10/24  
10  
  
 
1.2 Study  Objectives  and End Points  
 
1.2.1 Primary Objectives  
 
To determine whether  rimegepant,  an orally  available competitive  inhibitor  of the CGRP 
receptor, results in improvement in psoriasis compared to placebo as assessed by the 
PASI instrument. 
 
1.2.2 Secondary Objectives  
 
To determine whether treatment of psoriasis with rimegepant significantly improves patient’s 
quality of life as assessed by the Dermatology Quality of Life Index (DQLI), itch score, and IGA instrument, as well as by a 50% improvement according to the PASI instrument. 
 
1.2.3 Exploratory  Objectives 
 
Explore  the pattern of PASI  score  over time during treatment.  
 
Describe  changes  in circulating CD4+ IL-17+ T cells during treatment  with rimegepant  or 
placebo.  
 
Describe  histologic  changes  in psoriasis  lesions  during treatment  with rimegepant  or 
placebo.  
 
1.2.4 Primary  Endpoints  
 
1. PASI  instrument  score.  
 
 
Assessments  will be made  at baseline and every  2 weeks  for 20 weeks.  
 
1.2.5 Secondary Endpoints  
 
1. To determine if the degree  of improvement  in subjects  given rimegepant  is at least  50% 
compared to the placebo group as assessed by the PASI instrument.  
 
2. To determine whether  rimegepant  significantly  improves  psoriasis  compared  to placebo 
as assessed by the Investigator’s Global Assessment (IGA) instrument.  
 
3. To determine whether treatment of psoriasis with rimegepant significantly improves 
patient’s  quality  of life as assessed  by the Dermatology  Quality  of Life Index  (DQLI). The 
DQLI instrument will be administered at baseline and every 2 weeks  for 20 weeks.  
 
4. To determine whether  rimegepant  significantly  improves  the degree of itching (itch score) 
for patients with psoriasis as compared to placebo.  
Protocol  #20-07022368  
Version  Date 5/10/24  
11  
  
 
 
 
2. Background  
 
2.1 Disease  
 
Psoriasis is a common inflammatory skin disorder characterized by erythematous,  scaly 
lesions  that may occur  anywhere  but have  a predilection for the scalp,  extensor  surfaces of 
the extremities, especially  the elbows and knees,  and the anogenital area (1).  Psoriasis can 
be considered a systemic inflammatory disorder and part of the metaboli c syndrome. It is 
frequently associated with  a form  of arthritis, known as psoriatic arthritis (2).  It is associated, 
especially when severe, with cardiovascular disease, non- alcoholic fatty liver disease, 
inflammatory  bowel disease,  depression and lymphom as (2). Psoriasis affects 
approximately 2- 3% of the population. Mild and limited  psoriasis  can be treated with a 
variety  of topical agents  including corticosteroids,  calcipotriene,  topical retinoids,  crisaborole, 
amongst others  (3-5). When severe, treatment is primarily with immunosuppressive agents 
including methotrexate, cyclosporine, 6- thioguanine and,  more  recently,  a number  of 
biological agents that block tumor necrosis alpha,  interleukin- 23, interleukin- 17, the JAK- 
STAT signaling system, and phosphodiesterase inhibitors, or phototherapy (broad- band or 
narrow -band UVB radiation;  psoralen plus UVA radiation),  amongst  others  (3-5). All of 
these systemic medications and phototherapy have undesirable side effects caused by 
immunosuppression, gastrointestinal effects or other unwanted side effects. Thus, a need 
exists for safer effective systemic therapies.  
 
2.2 Investigational  Agent/Device,  or Surgical  Treatment/Method  
 
PK/Clin Pharm  
 
This study  is testing  the impact  of rimegepant  in the setting  of psoriasis.  Rimegepant  is a 
small molecule antagonist of the CGRP receptors, thus limiting CGRP signaling.  
Rimegepant  is approved for acute migraine.  After  administration of the 75 mg tablet,  time to 
maximum  plasma concentration (Tmax) occurs at a median of 1.9 h. The two clinical 
formulations  of rimegepant,  the tablet  and oral disintegrating tablet  (ODT),  are bioequivalent. 
The absolute  oral bioavailability  of rimegepant  in the fasted  state  is approximately  64%.  The 
effects of a high- fat meal on the tablet formulation showed that overall, a high -fat meal 
decreased the mean AUC and C max of rimegepant by  30% and 33% , respectively, and 
delayed the T max by approximately one hour. Based on the weight of evidence from  three 
positive Phase 3 studies in migraine conducted without food restrictions, rimegepant 75 mg, 
administered as a tablet or ODT, may be administered without regard to food.  
The clinical  dose of rimegepant  is 75 mg. Rimegepant  exposures  increased over the single 
dose range of 25 mg to 900 mg. Steady state is achieved by Day 2 following  once daily 
dosing with no meaningful accumulation. Rimegepant 75 mg has low to moderate PK 
variability,  with coefficient  of variation (CV%)  characterized as Cmax = 40% and AUC 0-inf = 
30% for the tablet. Based on population PK analysis, the elimination half-life in normal 
healthy subjects is 11 hours.  
 
The steady  state  volume  of distribution  averages  approximately  120.4 L. Rimegepant  is 
approximately 96% bound to human plasma proteins.  
Protocol  #20-07022368  
Version  Date 5/10/24  
12  
  
 
The primary  route of elimination is through the feces.  Rimegepant  is the primary  circulating 
component in plasma, with  88% to 92% unchanged  parent present throughout the first  
4 hours.  Over  longer  periods of  time, unchanged rimegepant  represents  approximately  77% 
of the  total administered dose with only low  quantifiable levels of circulating metabolites  of 
rimegepant. CYP3A4 is the primary metabolizing enzyme.  
 
2.3 Rationale  
 
Considerable evidence in both humans with ps oriasis  and animal models  of psoriatic 
dermatitis indicate that CGRP may play a key role  in the pathophysiology  of this disease. In 
human psoriasis, denervation, administration of  local anesthetics  or administration  of 
botulinus toxin to the site of skin bearing psoriasis causes improvement or resolution of the 
disease at those sites demonstrating the importance of innervation for expression  of the 
disease (6- 9). In two mouse models  of psoriatic  dermatitis,  innervation is also necessary for 
expression of the rash (10,11); in one mice are engineered to express the angiopoietin 
receptor Tie- 2 (10) and in the other imiquimod is applied to the skin of mice of certain strains  
(11). In each, a psoriasiform dermatitis results. In humans, plasma CGRP is elevat ed in 
psoriasis  patients  compared  to controls  (12), an increased  CGRP  content  of skin is noted in 
psoriatic lesions (13) and CGRP can be detected on the surface  of endothelial cells in 
lesional skin (13). In the Tie- 2 model of psoriasiform dermatitis, syst emic administration of 
CGRP  can retard  the loss of the rash by denervation of the skin (6). In the imiquimod  model 
of psoriasiform  dermatitis,  nerves  release  a factor, likely  CGRP,  that is key for  development 
of the rash (14,15). Recent work from our laboratory has shown that CGRP treatment of endothelial  cells endows  them  with the capacity,  acting  as bystanders,  to bias the outcome 
of antigen presentation away  from the Th1 pole towards  Th17 -type immunity  (16). This may 
be relevant to psoriasis as psoriasis is an IL- 17/Th17 cell mediated disorder.  For all of these 
reasons, a trial of an agent that interrupts CGRP -signaling in psoriasis is warranted. In this 
regard, rimegepant  is approved for use in humans  for the treatment  of migraine  and is safe 
and well -tolerated (17). For all of these reasons, a trial of an agent that interrupts CGRP 
signaling in psoriasis is warranted.  
 
2.4 Risk/Benefit  Assessment  
 
2.4.1 Known  Potential  Risks  
 
From  the package  insert  of Nurtec  (rimegepant):  
 
The most  common  adverse reaction in Study  1 was nausea (2% in patients  who 
received NURTEC  ODT  compared to 0.4%  of patients  who received  placebo).  
 
Hypersensitivity,  including  dyspnea and severe  rash,  occurred  in less than 1% of 
patients treated with NURTEC ODT  
 
Hypersensitivity reactions, including dyspnea and rash, have occurred with NURTEC ODT 
in clinical studies. Hypersensitivity reactions can occur days after administration, and 
delayed serious hypersensitivity has occurred.  
 
Concomitant administr ation of rimegepant with strong inhibitors of CYP3A4 results in a 
significant increase in rimegepant exposure.  
Protocol  #20-07022368  
Version  Date 5/10/24  
13  
 Concomitant  administration  of rimegepant  with moderate inhibitors  of CYP3A4  may 
result in increased exposure of rimegepant.  
 
Concom itant administration  of rimegepant  with strong  or moderate inducers  of CYP3A  can 
result  in a significant  reduction in rimegepant  exposure,  which  may lead to loss of efficacy.  
 
Rimegepant is a substrate of permeability glycoprotein (P -gp) and Breast  Cancer 
Resistance  Protein (BCRP)  efflux  transporters.  Concomitant  administration of  rimegepant 
with inhibitors of P -gp or BCRP may result in a significant increase in rimegepant 
exposure.  
 
Potential subjects on any  medication that  is a strong or moderate inhibitor of 
CYP3A,  a strong  or moderate inducer  of CYP3A  or an inhibitor  of p-gp or BCRP 
will be excluded from participation in the study.  
 
2.4.2 Known  Potential  Benefits  
 
Rimegepant  is effective  as treatment  for migraine.  
 
2.4.3 Assessment  of Potential  Risks  and Benefits  
 
There is a medical  need for effective  systemic treatments  for psoriasis with better  safety 
profiles than currently available agents. Rimegepant has been shown to be safe and 
effective for treatment of migraine events. It has t he potential to be a safe and, based on 
preclinical studies, an effective systemic treatment for psoriasis.  
 
 
2.5 Correlative Studies  Background  
 
Not applicable.  
 
3. Study  Design  
 
3.1 Overall  Design  
This is a phase 2, randomized double- blind controlled pilot study  to assess whether 
there is clinical improvement in psoriasis after administration of a small molecule CGRP 
receptor inhibitor, rimegepant, compared to placebo. Rimegepant and placebo will be 
identical appearing 75 mg tablets/ODTs administered orally every other day. The study 
will be conducted solely at Weill Cornell Medicine and last 20 total weeks with 16 weeks 
of medication or placebo  administration and 4 additional  weeks  of follow- up. Subjects  will 
present to clinic every 2 weeks  for clinical asse ssment using the PASI, IGA, DLQI, and 
Itch Score instruments,  along with skin biopsies on Week 1 and Week 16.  Subjects will 
be asked to bring their medications to these visits  for pill counts  to determine if any 
doses of medication were forgotten.  
Protocol  #20-07022368  
Version  Date 5/10/24  
14  
 Study  medications will  be dispensed on Day 0  and Day 56.  Thirty will  be dispensed  eachtime 
so that enough medication  is provided in case  of a minor  delay  in a scheduled appointment.  
 
Areas of psoriasis in each subject will be photographed at baseline and two very similar 
appearing lesions  will be identified for possible biopsy  of one on Day 1 and the other at the end 
of Week  16. Prior  to starting  treatment  and at the end of week  16 they will have  blood  taken for 
quantification of the proportion of circulating CD4+ T cells that are IL- 17+ . 
 
At the option of each subject,biopsies  of the psoriatic  lesions  previously identified (one before 
treatment and one on week 16) will be performed for light microscopy analysis. Biopsies are 
performed by cleaning the skin carefully  with an antiseptic, then injecting  a small amount of 
local anesthetic  into the skin. A 3 or 4 mm diameter  trephine punch is then used to remove  a 
very small  piece of skin. The surgicaldefect  is then closed  with 1 or 2 sutures  that are removed 
2 weeks later.  
 
Subjects  will return on weeks 18 and 20 for final assessments. Subjects  must  also agree to 
avoid the sun including  but not limited  to activities  such  as sunbathing,  swimming  or performing 
other  activities in sunlight  for long periods of  time (e.g., > 20 minutes)  for the duration of the 
study. Brief exposure during normal activities is permitted.  
 
Subjects who complete the 20- week protocol will have the opt ion of entering a 12 weeks, open label 
extension of the study  in which  they will take  75 mg of Rimegepant  every  other  day for 12 weeks.  If rolling 
into the extension prior to visit 11, they can combine visit 11 and 12. Otherwise,  subjects  have the option to 
enroll into the extension up to 2 weeks after visit 11. They will have the same assessments as in the 
previous  portion of the study  every  4 weeks  including  an EKG.  The inclusion  and exclusion criteria  remain 
the same.  
 
3.2 Justification for Dose  
 
The dose to be employed  (rimegepant  75 mg every other  day) has been shown  to be safe 
and effective for the treatment of acute migraine.  Rimegepant 75 mg every other day (up to 
one year) has been studied in the treatment of migraine prevention.  
 
3.3 End of Study  Definition  
 
A participant is considered to have completed the study  if he or she has completed  all 
phases of the study including the last visit or the last scheduled procedure shown in the 
Schedule  of Assessments  (SoA),  Section 6.1. The end of the study is defined as completion 
of the last visit or procedure shown in the SoA in the trial globally.  
 
4. Subject  Selection  
 
4.1 Study  Population  
 
Subjects  with a diagnosis  of psoriasis  who meet  the inclusion  and exclusion  criteria  will be 
eligible for participation in this study.  
 
4.2 Inclusion Criteria  
Protocol  #20-07022368  
Version  Date 5/10/24  
15  
  
1. Male  or female  patients  with at least  3% body  surface are involved with psoriasis and a 
PASI score > 5. 
2. Between 18 and 75 years  of age. 
3. Documentation of a definite diagnosis  of psoriasis by  a dermatologist  or biopsy.  
4. For women  of childbearing  potential,  a negative urine  pregnancy  test within  48 hours  of 
randomization.  Female subjects should not have attempted to become pregnant in the 
month  prior to exposure  to rimegepant  and agree not to attempt  to become 
pregnant  for 8 weeks  after exposure  to rimegepant.  
 
5. A valid form of contraception must  be documented for men and women  of child- 
bearing potential.  
a. The two methods  for women  of childbearing potential  should include:  
i. One barrier method (for example, Diaphragm  with spermicidal gel, 
condom  with spermicidal  gel, cervical  caps  or intrauterine  devices  placed 
for at least four weeks before sexual intercourse); AND  
ii. One additional  method.  The other  method could  include hormonal 
contraceptives, or second barrier method as listed above.  
b. The two options  for men of childbearing potential  should include:  
i. Simultaneous  use of male  condom,  and for the female  partner,  hormonal 
contraceptives (for example, birth control pills, implants, patch, depot 
injection, used since at least 4 weeks)  or intra-uterine contraceptive 
device (placed since at least 4 weeks) before sexual intercourse; OR Simultaneous use of male condom,  and for the female  partner, 
diaphragm with intravaginally applied spermicide.  
 
 
4.3 Exclusion Criteria  
 
1. Any ongoing medical illness or condition that places the participant at higher risk for 
adverse outcomes  or inability  to complete  study  procedures  in the opinion  of the study 
investigator.  
2. Pregnancy  or breastfeeding.  
3. Known autoimmune disorders  other  than psoriasis.  
4. Current  use of corticosteroids  or immunosuppressive medications  (for any reason).  
5. Immunodeficiency diseases.  
6. Use of any biologic  agent/monoclonal antibody  within  5 half-lifes prior to baseline.  
7. Ultraviolet light  treatment, cyclosporine,  oral corticosteroids, methotrexate, oral retinoids, 
mycophenolate mofetil, thioguanine, hydr oxyurea,  sirolimus or azathioprine within the 4 
weeks prior to baseline or had topical psoriasis treatment within the previous 2 weeks  prior 
to baseline.  
8. Participation  in another  clinical  trial involving  an investigational  drug within  the last 30 
days prior to baseline.  
9. Inability  for woman  of child-bearing potential  to use an effective  form of contraception if 
sexually active.  
10. Use of any medication that is a strong or moderate inhibitor of CYP3A, a strong or 
moderate  inducer of CYP3A, or an inhibitor of glycoprotein (P-gp) or  Breast  Cancer 
Resistance Protein (BCRP). Please see Section 7.8 for more information.  
11. Subject  history  with current  evidence of uncontrolled,  unstable or recently  diagnosed 
cardiovascular  disease,  such  as ischemic  heart  disease,  coronary  artery  vasospasm, 
and cerebral ischemia. Subjects with myocardial infarction (MI), acute  coronary 
syndrome  (ACS),  percutaneous  coronary  intervention (PCI),  cardiac  surgery,  stroke  or 
transient ischemic attack (TIA) during 6 months (24 weeks) prior to screening.  
Protocol  #20-07022368  
Version  Date 5/10/24  
16  
 12. Uncontrolled hypertension or uncontrolled diabetes  (however,  subjects  can be included 
who have stable hypertension and/or diabetes for 3 months  (12 weeks) prior to 
screening). Blood pressure greater than 150 mm Hg systolic or 100 mm Hg diastolic 
after 10 minutes of rest is exclusionary  
13. Subjects with an active episode of major depressive episode within the last 6 months are 
ineligible. Subjects with major depressive disorder or any anxiety disorder are eligible only if they 
are on stable medication for each disorder for at least 3 months prior to theScreening visit.  
14. Subject  has a history  or diagnosis  of Gilbert’s  Syndrome or any other  active  hepatic  or 
biliary disorder  
15. Hematologic  or solid malignancy  diagnosis  within  5 years  prior to screening.  Subjects 
with a history of localized basal cell or squamous cell skin cancer are eligible for the 
study if they are cancer -free prior to the screening visit in this study.  
16. Subject  has current  diagnosis  of major  depressive  disorder  requiring  treatment  with 
atypical antipsychotics, schizophrenia, bipolar disorder, or borderline personality 
disorder.  
17. History  of gallstones  without  cholecystectomy.  
18. Subject  has current  diagnosis  of major  depressive  disorder  requiring  treatment  with 
atypical antipsychotics, schizophrenia, bipolar disorder, or borderline personality 
disorder.  
19. Subject  has end-stage kidney  disease.  
20. The use of CGRP antagonists (biologic [e.g. Aimovig™, Emgality® and Ajovy ™, 
VyeptiTM] or small  molecule  [ e.g. Ubrelvy ™ {ubrogepant]])  other  than rimegepant  is 
prohibited during the study.  
21. Concomitant use of atypical antipsychotics such as Abilify (aripiprazole), Zyprexa 
(olanzapine),  Seroquel  (quetiapine),  Geodon (ziprasidone),  or Risperdal  (risperidone).  
22. Depakote/Depakene (divalproex/valproic  acid/valproate)  is prohibited during  the study.  
23. Concomitant  use of LAMICTAL  (lamotrigine)  is prohibited during the study.  
24. Concomitant  use of Modafinil  (PROVIGIL®)  is prohibited during  the study.  
25. Exclusionary  screening  lab test findings:  
 
• Serum  bilirubin  (Total,  Direct  or Indirect)  > 1 x ULN (Only  abnormal  values  of between 1- 
1.5x ULN  may be repeated once for assessment of eligibility prior to randomization)  
• AST or ALT > 1 x ULN (Only abnormal  values  of between 1-1.5x ULN  may be repeated 
once for assessment of eligibility prior to randomization)  
• Neutrophil  count  ≤ 1000/μL (or equivalent)  
• HbA1c  > 6.5%  
 
 
4.4 Lifestyle Considerations  
 
Not applicable.  
 
4.5 Screen  Failures  
 
Individuals who do not  meet  the criteria for participation in this trial (screen failure) because 
of a use of a disqualifying  medication may be rescreened after the required period of not 
using that medication. Rescreened participants will be assigned the same  participant 
number as for the initial screening.  
Protocol  #20-07022368  
Version  Date 5/10/24  
17  
 4.6 Strategies  for Recruitment  and Retention  
5. Registration Procedures  
5.1 Subject  Registration (WCM  only)  
 
Subjects  will be registered  within  the WRG -CT as per the standard operating procedure 
for Subject Registration.  
 
5.2 Subject  Registration (Sub -sites)  
 
Not applicable.  
 
6. Study  Procedures  
 
6.1 Schedule  of Assessments  
Visit Number:  1 2 3 4 5 6 7 8 9 10 11 
 Pre- 
Study  Day 
0 Wk 
2 Wk 
4 Wk 
6 Wk 
8 Wk 
10 Wk 
12 Wk 
14 Wk 
16 Wk 
18 Wk 
20  
Informed  consent  X             
Evaluation for Entry  X             
Demographics  X             
Medication  
History  X X X X X X X X X X X X  
Medical  History*  X X X X X X X X X X X X  
Height  X             
Weight  X             
Vital Signs  X             
Skin Exam  + Photos*  X X X X X X X X X X X X  
PASI  Score  X X X X X X X X X X X X  
IGA Score  X X X X X X X X X X X X  
DLQI  Score  X X X X X X X X X X X X  
Itch Score  X X X X X X X X X X X X  
Urine  pregnancy  test X X X X X X X X X X X X  
CMP,  CBC  w/Diff,  X         X    
T Cell FACS,  Biopsy  of 
Skin Lesion   X            
HIV Serology,  HbA1c  X             
Protocol  #20-07022368  
Version  Date 5/10/24  
18  
  
 
Assess  Adverse  Event   X X X X X X X X X X X  
ECG  X   X  X  X  X    
Randomization  X             
Medication 
Dispensation  X    X        
Pill Counts    X X X X X X X X    
All visits have a +/- 2-day window.  Each visit is first day of the week  indicated.  
 
 
 

Protocol  #20-07022368  
Version  Date 5/10/24  
19  
 *Subjects  enrolling in extension prior  to visit 11 can combine  visit 11 and 12. 
**Skin Exam:  The entire  glabrous  skin surface  will be examined.  
**Photography:  Photographs  will be taken  to demonstrate  the extent  and morphology of lesions 
of psoriasis. 
**Medical  History:  Characteristics  of the patient’s  psoriasis  will be obtained (duration, areas  of 
involvement, past therapies and degree of itch). History of active medical problems, any 
immunosuppressive  disorders  will be queried. Family  history of psoriasis  or other  inflammatory 
skin diseases will also be obtained. 
6.1.1 Screening Visit (2-10 days before start  of treatment ) 
• Informed consent  
• Demographics  
• Medication history  
• Medical  history  
• Skin exam  + photos  
• PASI  Score  
• IGA Score  
• DLQI  Score  
• Itch Score  
• Beta-HCG  
• HIV Serology  
• CBC w/Diff, CMP, Hemoglobin  A1c 
• ECG  
6.1.2 Treatment  Phase  
Eligible  subjects will be randomly  assigned to rimegepant  or placebo treatment 
groups in a 1:1 ratio using a stratified permuted block randomization scheme 
developed by the data manager/study statistician.  
 
6.1.2.1  Visit 1 (baseline;  Day 0) 
 
• Medication history  (changes)  
• Medical  history  (changes)  
• Skin exam  + photos  
• PASI  score  
• IGA Score  
• DLQI  Score  
• Itch Score  
• Adverse Events  Assessment  
• Concomitant  medication  
 
6.1.2.2  Visits  2-12 (± 2 day(s))  
 
• Medication history  (changes)  
• Medical  history  (changes)  
• Skin exam  + photos  
• PASI  score  
• IGA Score  
• DLQI  Score  
Protocol  #20-07022368  
Version  Date 5/10/24  
20  
 • Itch Score  
• Adverse Events  Assessment  
• Concomitant  medication  
• ECGs  will be obtained on Visits  3,5,7 and 9. 
 
6.1.3 Follow -up Phase  
 
Visits  11 and 12 are follow -ups after completion of the treatment  phase 
 
Extension  Phase  
 
Visits  13-15 have the same  assessments  as visits  2-12 except  they will 
have a frequency of every 4 weeks.  
 
7. Study  Intervention  
 
 
7.1 Study  Intervention/Device Description  
 
In this protocol, the investigational product will come in 2 forms either tablet or ODTs. 
Both active forms of tablets and ODTs will have 75mg of rimegepant and both 
formulations provide bioequivalent exposures, thus support equivalent PK 
performance. The tablets will be provided in 30 count HDPE bottles and labeled in a 
double- blind fashion that is identical to placebo tablets. The ODTs are packaged into 
multi- laminated  blisters  sealed with a foil backing and labeled in a double- blind  fashion 
that is identical to placebo ODTs.  Because the blister packs are  in units of 8, 32 ODTs 
of rimegepant or placebo will be distributed. Any leftover investigational product will be 
returned to the study team during visits 5, 9 and if applicable, extension visit 14.  
 
 
The investigational  product  will be shipped to the pharmacy  by Pfizer  Inc. and should be 
stored in a secure area according to local regulations. It is the responsibility of the 
investigator to ensure that investigational product is only dispensed to study subjects. 
The investigational  product  must be  dispensed only from official study  sites by 
authorized personnel according to local regulations.  
 
7.2 Availability  
 
The full amount of Rimegepant and placebo will be supplied by Pfizer, Inc. and 
shipped to the site pharmacy  prior to the initiation  of the trial. If  additional  product  is 
required, contact the sponsor directly.  
 
7.3 Acquisition and Accountability  
 
Agent Inventory Records/Device Logs  – The investigator, or a responsible party 
designated by the investigator, will maintain a careful record of the inventory and disposition of all agents/device received from Sponsor  on a Drug  Accountability  Record 
Form (DARF) or Device Log.  
Protocol  #20-07022368  
Version  Date 5/10/24  
21  
  
7.4 Formulation,  Appearance,  Packaging,  and Labeling  
 
The rimegepant  active  and placebo tablets are packaged in 30 count  HDPE  bottles  and 
will have a blinded label which will include a unique bottle number, the product name, 
labeling lot number, storage conditions  and dosing directions.  The unique  bottle  number 
is linked to the treatment arm in a blinded fashion. The rimegepant active and placebo 
ODTs  are packaged in 8-count multi -laminated blisters  backed with foil and will be labeled 
similarly t o the tablet bottles.  
 
7.5 Product  Storage  and Stability  
 
The investigational product should be stored at room  temperature according to 
conditions  on the clinical  label  in a secure area according to local regulations.  
 
It is the responsibility of the investigator to ensure that investigational product is only 
dispensed to study  subjects.  The investigational  product  must  be dispensed  only from 
official study sites by authorized personnel according to local regulations.  
 
If concerns  regarding the quality  or appearance of the study  drug arise,  do not dispense 
the study drug and contact the sponsor immediately.  
 
7.6 Preparation  
 
The investigational  product  will be assigned by the unblinded pharmacist  after patient 
randomization through use of  the unique bottle numbers.  The pharmacist  will add the 
appropriate subject number on the bottle label and provide it to the site staff for 
dispensation to the subject.  
 
7.7 Dosing and Administration  
 
Each subject will take a 75- mg tablet/ODT of rimegepant orally or a matching placebo 
tablet/ODT orally every other day for 16 weeks. Subjects will receive 30 tablets or  32 
ODTs of rimegepant or matching placebo in each bottle or four 8- count blister pack s at 
the initial visit after  the subject  is randomized.  The subject  will be instructed  to dose 
around the same time  every  other  day. The subject  must  bring  the bottle/blister  pack s 
back  for each visit for drug accountability.  A second 30 tablet  or 32 ODT supply will 
be dispensed at week 8. Pill counts will be performed at each visit to assess 
compliance.  
 
7.7.1 Dosing Delays/Dose Modifications  
 
For any serious  adverse  effects, dosing will be immediately  discontinued and 
appropriate care provided. Some nausea is expected.  
 
7.8 General  Concomitant  Medication and Supportive  Care  Guidelines  
 
Concomitant  administration  of rimegepant  with strong  inhibitors  of CYP3A4  results  in a 
significant increase in rimegepant exposure.  
CYP3A4 Inhibitors (Strong) Interacting Members: Atazanavir, Ceritinib, Clarithromycin, 
Cobicistat, Darunavir, Idelalisib, Indinavir, Itraconazole, Ketoconazole (Systemic),  Lopinavir,  
MiFEPRIStone,  Nefazodone,  Nelfinavir,  Ombitasvir,  Paritaprevir, 
Protocol  #20-07022368  
Version  Date 5/10/24  
22  
 and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, Posaconazole,  
Ritonavir,  Saquinavir,  Telithromycin,  Tucatinib,  Voriconazole  
Concomitant  administration  of rimegepant  with moderate  inhibitors  of CYP3A4  may result  in 
increased exposure of rimegepant.  
 
 
- CYP3A4 Inhibitors (Moderate) Interacting Members : Aprepitant, Conivaptan, 
Crizotinib,  DilTIAZem,  Dronedarone,  Duvelisib,  Erythromycin  (Systemic),  Fedratinib, 
Fluconazole, Fosamprenavir, Fosnetupitant, Grapefruit Juice, Imatinib, 
Isavuconazoni um Sulfate, Lefamulin, Letermovir, Netupitant, Nilotinib, Ribociclib, 
Schisandra, Verapamil  
 
Concomitant administration of rimegepant with strong or moderate inducers of CYP3A can result  in a significant  reduction  in rimegepant  exposure,  which may  lead to loss  of efficacy.  
 
- CYP3A4  Inducers (Strong) Interacting  Members:  Apalutamide,  CarBAMazepine, 
Enzalutamide, Fosphenytoin, Lumacaftor and Ivacaftor, Mitotane, PHENobarbital, 
Phenytoin, Primidone, RifAMPin  
- CYP3A4 Inducers (Moderate) Interacting Members: Bexarotene (Systemic), 
Bosentan, Cenobamate, Dabrafenib, Efavirenz, Eslicarbazepine, Etravirine, 
Lorlatinib,  Modafinil,  Nafcillin,  Pexidartinib,  Rifabutin,  Rifapentine,  St John's  Wort  
 
Rimegepant is  a substrate of permeability  glycoprotein (P-gp) and Breast Cancer 
Resistance Protein (BCRP) efflux transporters.  Concomitant  administration of rimegepant 
with inhibitors of  P-gp or BCRP may result  in a significant  increase in rimegepant  exposure.  
 
- BCRP/ABCG2  Inhibitors Interacting  Members:  Atazanavir,  Capmatinib, 
Clopidogrel, Cobicistat, CycloSPORINE (Systemic), Daclatasvir, Darolutamide, 
Dasabuvir, Elbasvir, Eltrombopag, Eluxadoline,  Fostamatinib,  Fostemsavir, 
Glecaprevir and Pibrentasvir, Grazoprevir, Lapat inib, Ledipasvir,  Leflunomide, 
Lopinavir,  Ombitasvir, Paritaprevir,  and Ritonavir,  Ombitasvir,  Paritaprevir,  Ritonavir, 
and Dasabuvir, Osimertinib, Regorafenib, Rolapitant, Simeprevir, Tedizolid, Teriflunomide, Velpatasvir, Voxilaprevir  
- P-glycoprotein/ABCB1 Inhibitors Interacting Members: Amiodarone, 
Azithromycin (Systemic), Capmatinib, Carvedilol, CycloSPORINE (Systemic), Daclatasvir, Dronedarone, Elagolix, Elagolix, Estradiol, and Norethindrone, 
Elexacaftor, Tezacaftor, and Ivacaftor, E liglustat, Erythromycin (Systemic), 
Flibanserin, Fostamatinib, Glecaprevir and Pibrentasvir, Ivacaftor, Lapatinib, 
Ledipasvir,  Neratinib,  Osimertinib,  Propafenone,  QuiNIDine,  QuiNINE,  Ranolazine, 
Rolapitant, Simeprevir, Tezacaftor and Ivacaftor, Tucatinib,  Velpatasvir, 
Vemurafenib, Verapamil  
Exceptions Clarithromycin,  Itraconazole,  Ketoconazole (Systemic),  Ombitasvir, 
Paritaprevir, and Ritonavir, Ritonavir  
 
Potential  subjects on any medication  that is a strong  or moderate inhibitor  of CYP3A, 
a strong or moderate inducer of CYP3A or an inhibitor of p -gp or BCRP will be 
excluded from participation in the study.  
Protocol  #20-07022368  
Version  Date 5/10/24  
23  
 All concomitant  medications  will be recorded  and/or  updated on subject  medication log 
throughout the course of the study and saved in subject binder, if applicable.  
 
7.9 Duration  of Therapy  and Criteria  for Removal  from  Study  
 
 
In the absence of treatment  delays  due to adverse event(s),  treatment  will continue for 
16 weeks or until one of the following criteria applies:  
 
• Disease  progression requiring intervention,  
• Intercurrent  illness  that prevents  further  administration of treatment,  
• Unacceptable  adverse event(s),  
• Subject  decides  to withdraw  from the study,  
• Initiation  of prohibited medication,  or 
• General  or specific  changes  in the subject’s  condition  render  the subject 
unacceptable for further treatment in the judgment of the investigator.  
 
7.10 Duration  of Follow  Up 
 
Subjects will be followed for 4 weeks after discontinuation of the investigative 
pharmaceutical  agent.  Subjects  removed from  study  for unacceptable adverse events 
will be followed until resolution or stabilization of the adverse event.  
 
7.11 Measures  to Minimize  Bias:  Randomization and Blinding  
 
Screening and Registration  into the Study Database  
Once  informed consent  has been  signed,  participants  will be registered into the study 
database. The study database will assign a participant’s PID  upon completion of the 
registration process.  
 
Randomization:  
Participants will be assigned a randomization number once the following has been 
accomplished:  eligibility  has been verified,  eligibility  has been confirmed by the study  PI, 
and eligibility CRF has been entered into the study database.  
 
Patients will be stratified based on severity of disease as measured by PASI scores<12 
(mild/moderate) or >=12 (Severe) at screening. Within each stratum, patients will be 
randomized at 1: 1 ratio to the two treatment arms using permuted block randomization 
with varying block  sizes. Randomiza tion codes will be shared to the study pharmacist at 
the initiation  of the trial. The randomization will be performed  by the statistician  who will 
alert the pharmacy in coordination with the study coordinator.  
 
Screening/Registration/Randomization into Study  Databases 
Appropriate CRFs must be completed for any participant  who signs  an informed 
consent. If a consented participant is  a screen  failure  and deemed  ineligible, the 
following  CRFs  must  be completed:  1) the Screening  CRF;  2) the Registration  CRF with 
the eligibility box checked “no”, 3) the Inclusion and Exclusion CRFs showing why the 
participant is ineligible, 4) the Off -Study CRF, 5) the Adverse Event CRF, 6) the 
Concomitant Medication CRF  and 7) the Verification CRF. If no Adverse Event and/or 
Concomitant  Medications  were  assessed  by the time the participant  is deemed  ineligible, 
the “NONE” box will be checked to complete both CRFs. All participants who sign an 
informed consent  must  formal ly go off study.  All participant  registration information will 
Protocol  #20-07022368  
Version  Date 5/10/24  
24  
 be entered into study  database.  If a participant  experiences  a serious  adverse  event 
during the screening process, an SAE form must be completed.  
 
Blinding  and Unblinding Method 
 
- Patients  and all clinical  evaluators  will be blinded  to treatment  assignment.  
- The Statistician  and the Study  Pharmacist  at the participating sites will not be blinded 
to treatment assignment.  
- Study assignments will be unblinded to the Study Investigators and Coordinators 
after all of the data are collected,  the study  database has been locked,  and analyses 
are completed.  
- Emergency  unblinding will occur  if the participant’s  physician deems  that unblinding 
is necessary, such as in the case of unacceptable toxicity thought to be related to the 
study agent or progressive disease.  
- The Independent Medical Monitor  will also  be blinded unless unblinding is  warranted 
(if the participant’s  physician deems  that unblinding  is necessary,  or after all of the 
data are collected and the study database has been locked).  
- The date and reason for breaking the blind  must  be documented  in the study 
database.  
7.12 Study Intervention/Follow -up Compliance  
 
Subject  will be asked  to complete  a log documenting the date and time that the study 
medication is taken (every other day).  
 
Pill counts  will be done at each visit. 
 
If necessary, 3 attempts will be made to get subject to return for study follow -up 
Appointments.  If the patient  does  not respond to 3 attempts  he/she will be considered 
“lost to follow -up” and no longer participating in the study.  
 
8. Study  Intervention  Discontinuation  and Participant  Discontinuation/Withdrawal  
 
8.1 Discontinuation of Study  Intervention  
 
Subjects  will be withdrawn  from study treatment  permanently  for the following  reasons:  
 
1. Development  of any hypersensitivity  phenomena that may be related to the study 
medication.  
2. Excessive nausea  making  continuation of participation in the study  impossible.  
3. Development  of any intercurrent  illness  or medical  need to take a medication  such 
that exclusion criteria apply.  
4. Occurrence of pregnancy  in a female  subject.  
5. If any clinical adverse event  (AE),  laboratory  abnormality,  or other  medical  condition 
or situation occurs such that continued participation in the  study  would  not be in the best 
interest of the participant  
6. Disease  progression  which  requires  discontinuation  of the study  intervention 
7. If the participant  meets  an exclusion criterion (either  newly  developed  or not 
previously recognized) that precludes further study participation  
Protocol  #20-07022368  
Version  Date 5/10/24  
25  
  
Subjects  will be referred for appropriate medical  care for any adverse effects. 
 
Subjects  will continue to be followed  for assessment  of disease severity until the 20- 
week period is over.  
 
Discontinuation of treatment does not mean discontinuation from the study, and 
remaining study  procedures  (assessments  of disease severity)  will be completed as 
indicated by the study protocol.  
 
If a clinically significant finding is identified (including, but not limited to changes from 
baseline) after enrollment, the investigator or qualified designee will determine if any 
change in participant  management  is needed.  Any new clinically  relevant  finding will be 
reported as an adverse event (AE).  
 
Criteria  for interrupting the study:  We will have a study  monitoring  committee  (SMC) 
consisting of the study  PI, the medical  monitor  and 1 investigator  not directly  involved in 
the conduct of this study. This committee will review all Grade 3 or 4 events, and all 
SAEs in real time. We will pause enrollment of new participants if there is 1 or more 
Serious Adverse Events that are at least possibly related to study drug, or 2 or more 
Grade 3 or 4 events at least possibly related to study drug. The enrollment of 
participants will not resume until the SMC reviews the adverse events and agrees 
unanimously to resume enrollment.  
 
8.2 Participant  Discontinuation/Withdrawal  from  the Study  
 
Participants  are free to withdraw  from participation in the study at any  time upon request. 
An investigator  may discontinue or withdraw a participant  from the study  for the  following 
reasons:  
1. Pregnancy.  However,  subjects  will be followed  until the end of the pregnancy.  
2. Significant  study  intervention non-compliance (failure  to take medications,  refuses  to 
allow study procedures).  
3. Participant lost  to follow -up after 3 attempts  to contact  subject  to schedule study  visit. 
 
The reason for participant  discontinuation or withdrawal from the study  will be recorded 
on the Case  Report  Form  (CRF).  Subjects  who sign the informed consent  form and are 
randomized but do not receive the study intervention may be replaced. Subjects who 
sign the informed  consent  form, and are randomized and receive the study  intervention, 
and subsequently  withdraw,  or are withdrawn  or discontinued from the study  will not be 
replaced.  
 
8.3 Lost  to Follow  Up 
 
A participant  will be considered lost to follow- up if he or she fails to return  for a 
scheduled visit and is unable to be contacted by the study site staff.  
The following  actions  must  be taken  if a participant  fails to return  to the clinic  for a 
required study visit:  
 
• The site will attempt  to contact  the participant  and reschedule the missed  visit within 
2 days and counsel the participant on the importance of maintaining the assigned 
visit schedule and ascertain if the participant  wishes  to and/or  should continue in the 
study.  
Protocol  #20-07022368  
Version  Date 5/10/24  
26  
  
• Before a participant  is deemed lost to follow -up, the investigator  or designee will 
make every effort to regain contact with the participant (where possible, 3 
telephone calls). These contact attempts should be documented in the 
participant’s medical record or study file.  
• Should the participant  continue to be unreachable,  he or she will be considered  to 
have withdrawn from  the study with a primary reason of lost to follow -up. 
 
9. Correlative/Special  Studies  
Not applicable.  
10. Measurement  of Effect  
10.1 Response Criteria  
Not applicable.  
10.2 Duration  of Response  
Not applicable.  
10.3 Progression -Free  Survival  
Not Applicable.  
10.4 Other  Response 
Parameters  
Not Applicable.  
 
11. Data  Reporting / Regulatory  Considerations  
 
11.1 Data  Collection  
The data collection plan for this study  is to utilize  REDCap  to capture all treatment, 
toxicity, efficacy, and adverse event data for all enrolled subjects.  
 
11.1.1  REDCap  
REDCap (Research Electronic Data Capture) is  a free data management software 
system  that is fully supported by the Weill -Cornell  Medical  Center  CTSC.  It is a tool for 
the creation of customized, secure data management systems that include Web- based 
data- entry  forms,  reporting tools,  and a full array  of security features  including  user and 
group based privileges, authentication using institution  LDAP  system , with  a full audit 
trail of data manipulation and export procedures.  REDCap  is maintained on CTSC - 
owned servers that are backed up nightly and support encrypted (SSL -based) 
connections.  Nationally, the software is developed, enhanced and supported throug h a 
multi -institutional consortium led by the Vanderbilt University CTSA.  
 
11.2 Regulatory  Considerations  
11.2.1  Institutional  Review  Board/Ethics Committee  Approval  
 
As required by local regulations,  the Investigator  will ensure all legal  aspects are covered, 
and approval of the appropriate regulatory bodies obtained, before study initiation.  
Protocol  #20-07022368  
Version  Date 5/10/24  
27  
  
Before initiation of the study  at each  study  center,  the protocol,  the ICF, other  written 
material given to the patients, and any other relevant  study  documentation  will be 
submitted to the appropriate Ethics Committee. Written approval of the study and all 
relevant  study information  must  be obtained before the study center  can be initiated or  the 
IP is released  to the Investigator.  Any necessary  extensi ons or renewals  of IRB approval 
must be obtained for changes  to the study, such  as amendments  to the protocol, the 
ICF, or other study documentation. The written approval of the IRB together with the 
approved ICF must be filed in the study files.  
The Inves tigator will  report promptly  to the IRB any  new information that may  adversely 
affect the safety of the patients or the conduct of the study. The Investigator will submit  written  
summaries  of the study  status  to the IRB as required.  On completion  of the study, the IRB 
will be notified that the study has ended.  
 
All agreed  protocol  amendments will be clearly  recorded on a protocol  amendment  form 
and will be signed and dated by the original protocol approving signatories. All protocol 
amendments will be sub mitted to the relevant institutional IRB for approval before 
implementation, as required by local regulations. The only exception will be when the 
amendment  is necessary  to eliminate an immediate  hazard to the trial participants.  In this 
case, the necessary action will be taken first, with the relevant protocolamendment following 
shortly thereafter.  
Once  protocol  amendments  or consent  form modifications  are implemented at the lead 
site, Weill Cornell Medicine, updated documents will be provided to participating sites, as 
applicable.  Weill  Cornell  Medicine must  approve  all consent  form changes  prior to local 
IRB submission.  
An IND, including relevant  study  documentation,  will be submitted to the FDA,  according 
to national requirements, for review and approval before the beginning of the study. On 
completion of the study, the FDA will be notified that the study has ended.  
 
11.2.2  Ethical  Conduct  of the Study  
 
The Investigators and all parties involved should conduct this study in adherence to the ethical 
principles based on the Declaration of Helsinki, GCP, ICH guidelines and the applicable national 
and local laws and regulatory requirements.  
 
This study will be conducted under a protocol reviewed and approved by  the applicable  ethics 
committees and investigations will be undertaken by scientifically and medically qualified 
persons, where the benefits of the study  are in proportion to the risks.  
 
11.2.3  Informed Consent  
 
The investigator or qualified designee must obtain documented consent acc ording to ICH - GCP 
and local regulations, as applicable, from each potential subject or each  subject’s  legally 
authorized representative prior to participating in the research study. Subjects who agree  to 
participate will sign the approved informed consent  form and will be  provided  a copy of the 
signed document.  
 
The initial ICF, any subsequent revised written ICF and any written information provided to the 
subject must approved by IRB prior to use. The ICF will adhere to IRB requirements, applicable laws and regulations.  
Protocol  #20-07022368  
Version  Date 5/10/24  
28  
  
 
 
11.2.4  Compliance with Trial Registration and Results  Posting Requirements  
 
Under the terms of the Food and Drug Administration Modernization Act (FDAMA) and the 
Food  and Drug  Administration  Amendments  Act (FDAAA) , the Sponsor -Investigator  of the trial 
is solely responsible for determining whether the trial and its results are subject to the 
requirements for submission to http://www.clinicaltrials.gov . Information posted will allow 
subjects to identify potentially appropriate trials for their disease conditions and pursue participation by calling a central contact number for further information on appropriate trial 
locations and trial site contact information.  
 
11.2.5  
Record  Retention  
 
Essential  documents  are those documents  that individually  and collectively permit 
evaluation of the study and quality of the data produced. After completion of the study, all 
documents and data relating to the study will be kept in an orderly manner by  the Investigator  
in a secure study  file. Essential  documents  should be retained  for 2 years after the final 
marketing approval in an ICH region or for at least 2 years since the discontinuatio n of clinical 
development of the IP. In  addition, all subjects  medical records and  other  source  
documentation will be kept for the maximum  time permitted  by the hospital, institution, or 
medical practice.  
 
12. Statistical  Considerations 
 
12.1 Study  Design/Endpoints  
 
This is  a randomized, double- blind, placebo- controlled  phase II study  to examine  the 
efficacy of rimegepant, an orally available competitive inhibitor of the CGRP  receptor, in 
patients  diagnosed with psoriasis.  Patients  in each  strata  of disease  severity  as defined by 
baseline PASI score (<12, or >=12) will be randomized at 1:1 ratio to receive  16-week 
treatment of either rimegepant or placebo. The primary  endpoint  includes  the percent 
reduction in PASI score post-treatment measured at week  16 from baseline  defined as 
100%  x (PASI.pre -PASI.post)/PASI.pre. Secondary  endpoints  include  PASI50,  an indicator 
of whether a patient had at least 50% improvement in PASI score at week 16 post -treatment 
compared to baseline, the reductio n (i.e., the difference) in the Investigator’s  Global 
Assessment (IGA) score post treatment  from baseline,  change in Dermatology  Quality  of 
Life Index (DQLI) at week  16 post treatment compared to baseline, change  in Itch Score 
post treatment from baseline,  and the overall patterns of change in PASI scores, IGA  scores 
and DQLI scores measured longitudinally.  
 
12.2 Sample  Size/Accrual  Rate 
 
The primary objective of the study is to examine if patients  receive  the rimegepant treatment 
had greater improvement in  psoriasis in terms of the primary endpoints compared to patients 
received the placebo. The primary endpoints  include  both the percent reduction in PASI 
score  post-treatment from  baseline  and the change IGA score  post-treatment from  baseline.  
 
The sample size is determined to ensure adequate power to detect clinically meaningful 
differences  in the co-primary  endpoints  between the treatment arms. With  a sample  size of 
30 patients (15 per treatment arm), we will have 80%  power to detect an effec t size as small  
Protocol  #20-07022368  
Version  Date 5/10/24  
29  
  
as 1.06 using a two- sample t -test at a two -sided significance level of 0.05 for each of the 
primary endpoint. This level of effect size corresponds to >21%  differences in the percent 
reduction in PASI scores post treatment from baseline between the two treatment arms 
assuming  the standard deviation of the  percent reduction in PASI score  is about 20%  which 
is likely to be a conservative estimate  based on published results from  trials in patients  with 
moderate to severe disease.  This level of effect size also corresponds  to a difference  of 0.5 
in the change of IGA scores between the two study arms assuming the standard deviation of 
change is around 0.5. Accounting for a dropout rate of 25% a total of 4 5 patients will be 
recruited.  
 
The study  expects to accrue  5 patients  per month and accrue  all study  patients  within  6-10 
months.  
 
12.3 Stratification  Factors  
 
Patients  will be stratified  based on severity of disease  as measured  by PASI  scores<12  or 
>=12  at screening.  Within  each stratum, patients  will be randomized  at 1: 1 ratio to the two 
treatment arms using permuted block randomization with varying block size.  
 
12.4 Analysis of Endpoints  
 
12.4.1  Analysis of Primary  Endpoints  
 
The primary endpoint is the week 16 PASI score. We  will calculate  the percent reduction in 
week 16 PASI scores post treatment from  baseline. Summary  statistics in terms  mean, 
standard deviation,  median  and range or inter-quartile range will be generated for each study 
arm. Between treatment arm differences will be evaluated using a two- sample t -test or the non-  
parametric  Wilcoxon  rank sum test where  appropriate.  The primary  analysis  will be carried 
out on an intention- to-treat basis. Last value carried forward will be used to impute for patients 
missing  week 16 measurements. Per -protocol analysis  will also  be carried out amongpatients 
who are deemed compliant to treatment (defined as at least 75% of doses taken asmeasure by 
pill counts) and had both baseline and week  16 measurements  will also be carried out using 
similar statistical methods. P -values less  than 0.05 will be  considered statistical significant.  
 
12.4.2  Analysis of Secondary  Endpoints  
 
Quantification of subjects in each  arm achieving  PASI50  at week  16, defined as achieving  
>=50%  reduction  in PASI  scores measured  at week  16 post treatment  from baseline,  will be 
summarized.  Summary statistics including  count and proportion in each  treatment arm  will be 
provided for patients  enrolled in each arm. Differences  in proportions  between treatment  arms 
will be summarized along with 95% confidence interval.  Exploratory  comparison  will be 
carried out using Fisher’s exact test.  
 
For change in IGA  scores  at week  16 post treatment from  baseline, summary  statistics  in 
terms  mean,  standard deviation,  median and range or inter-quartile range will be generated for 
each study arm. Between treatment arm  differences  will be  evaluated using  a two-sample  t- 
test or the non- parametric Wilcoxon rank sum test where appropriate.  
 
For change in DQLI  scores at week  16 post treatment  from baseline,  summary  statistics  in 
terms  mean,  standard deviation,  median  and range or inter-quartile range will be generated  
Protocol  #20-07022368  
Version  Date 5/10/24  
30  
 for each study arm.  Between treatment  arm differences  will be  evaluated using  a two-sample 
t-test or the non- parametric Wilcoxon rank sum test where appropriate.  
 
For change in Itch Scores  at week  16 post treatment from  baseline, summary  statistics  in 
terms  mean,  standard deviation,  median and range  or inter-quartile range will be generated 
for each study  arm. Between treatment  arm differences  will be evaluated using  a two-sample  t- 
test or the non- parametric Wilcoxon rank sum test where appropriate.  
 
For longitudinal  measurements  of the study  endpoints  obtained overtime,  patterns  of 
differences between treatment arms will be evaluated using linear mixed- effects or 
generalized linear -mixed effects models.  
 
For all these  study  endpoints,  the primary  analysis  will be carried out on an intention- to-treat 
basis. For endpoints concerning change at week 16 from  baseline, a conservative method for 
imputation such as last -value carried forward will be used for those missing measurements at 
week  16. For analysis  concerning longitudinal data, no  missing  imputation will be applied.  
Secondary  per protocol  analyses  will also be carried  out among patients  who complied to 
study treatments.  
 
12.5 Interim  Analysis  
 
Not applicable.  
 
12.6 Reporting and Exclusions  
 
12.6.1  Evaluation of Toxicity  
 
All subjects will be evaluable for toxicity from the time of their first treatment with the 
Investigational  Agent.  Consultation with the Biostatistics  Office  will allow  for completion 
of this section.  
 
12.6.2  Evaluation of Response  
 
All subjects included in the study  will be assessed  for response to treatment  if they have 
received at least 4 weeks of treatments.  
 
13. Adverse  Event  Reporting Requirements  
 
Adverse event (AE) monitoring and reporting is a routine part of every  clinical trial.  The 
investigator will b e required to provide appropriate information concerning any findings that 
suggest  significant  hazards,  contraindications,  side effects, or precautions  pertinent  to the safe 
use of the drug or device under investigation.  Safety will be monitored by evaluation of adverse 
events reported by subjects  or observed by investigators or  research staff, as  well as by other 
investigations such as clinical laboratory tests, x -rays, electrocardiographs, etc.  
 
13.1 Adverse Event  Definition  
 
An adverse  event  (also  referred to as an adverse experience)  can be any unfavorable 
and unintended sign (e.g., an abnormal laboratory finding),  symptom,  or disease 
temporally associated with the use of a drug, and does not imply any judgment about 
causality. An  adverse event can arise  with any use of  the drug (e.g., off -label use,  use in 
Protocol  #20-07022368  
Version  Date  5/10/24   
31 
 combination with another  drug)  and with any route of administration,  formulation,  or dose, 
including an overdose.  
 
13.1.1  Investigational  Agent  or Device  Risks  (Expected  Adverse  Events)  
 
 
1. Nausea.  
 
2. Rare  chance  of hypersensitivity  reaction.  
 
Any adverse  events  will be treated appropriately  in consultation  with the subject’s 
physician or other appropriate physicians.  
 
13.1.2  Adverse  Event  Characteristics and Related Attributions  
 
CTCAE  term (AE description)  and grade:  The descriptions  and grading scales  found 
in the revised NCI Common Terminology Criteria for Adverse Events (CTCAE) version  
5.0 will be utilized  for AE reporting.  A copy  of the CTCAE  version 5.0 can be 
downloaded from the C TEP web site ( http://ctep.cancer.gov ). 
 
• Attribution  of the AE: 
- Definite  – The AE is clearly  related to the study  treatment.  
- Probable  – The AE is likely  related to the study  treatment.  
- Possible – The AE may be related to the study  treatment.  
- Unlikely  – The AE is doubtfully  related to the study  treatment.  
- Unrelated – The AE is clearly  NOT  related to the study  treatment.  
 
13.1.3  Recording of Adverse  Events  
 
All adverse  events  will be recorded on a subject  specific  AE log. The AE log will be 
maintained by the research staff and kept in the subject’s research chart.  
 
13.1.4  Reporting  of AE to WCM  IRB 
 
All AEs occurring  on this study  will be reported to the IRB according to the IRB policy, 
which can be accessed via the following link: 
http://researchintegrity.weill.cornell.edu/forms_and_policies/forms/Immediate_Reporting  
_Policy.pdf . 
 
13.1.5  Reporting Events  to Participants  
 
Any adverse events  or serious  adverse events  will be reported to all subjects  orally  and 
in writing promptly.  
 
13.1.6  Events of Special  Interest  
 
Not applicable.  
 
13.1.7  Reporting of Pregnancy  
 
If any pregnancies  arise  during the course  of the study,  incidence  of pregnancy  should be 
reported to the IRB according to the IRB policy of Weill Cornell Medicine.  
 
76 
Protocol  #20-07022368  
Version  Date  5/10/24   
32  Pregnancy testing will be conducted at each study visit. If, following the baseline visit, it is subsequently  
discovered that a study  subject  is pregnant,  the subject  will be discontinued from the study and 
study medication will be stopped.  
 
The Investigator  and/or  Co-Investigator  will immediately  inform  the Independent  Medical  Monitor 
of the event  and report  the event  in accordance with the SAE reporting procedures  as described 
in Section 13.2.1 –  13.2.3  
 
 
13.2 Definition  of SAE 
 
SAEs include death, life threatening adverse experiences, hospitalization or 
prolongation of hospitalization, disability or incapacitation, overdose, congenital 
anomalies  and any other  serious  events  that may jeopardize the subject  or require 
medical or surgical intervention to prevent one of the outcomes listed in this 
definition.  
 
13.2.1  Reporting  of SAE  to IRB 
 
All SAEs  occurring  on this study  will be reported to the IRB according to the IRB policy, 
which can be accessed via the following link: 
https://research.weill.cornell.edu/sites/default/files/immediate_reporting_policy.pdf  
 
 
13.2.2  Reporting  of SAE to FDA  [For Protocols  Where WCMC  is the Sponsor - 
Investigator]  
 
IND application sponsor must report any suspected adverse reaction or adverse 
reaction to study  treatment  that is both serious  and unexpected.  Unexpected fatal 
or life -threatening suspected adverse reactions  represent especially  important 
safety  information and must  be reported to FDA as soon as possible  but no later 
than 7 calendar days following the sponsor’s initial receipt of the information.  
i. death,  
ii. a life-threatening adverse  event,  
iii. in-patient  hospitalization or prolongation of existing  hospitalization,  
iv. a persistent  or significant  incapacity  or substantial  disruption  of the ability 
to conduct normal life functions, or  
v. a congenital  anomaly  or birth defect  
 
Important medical events that may  not result in death, be life-threatening, or 
require hospitalization may be considered  serious  when,  based upon appropriate 
medical judgment, they may jeopardize the patient or research subject and may 
require medical or surgical intervention to prevent one of the outcomes listed as 
serious  
Protocol  #20-07022368  
Version  Date  5/10/24   
33   
 
 
 
 
 
Select  appropriate reporting branch below  
 
CDER  INDs : 
 
Food  and Drug  Administration 
Center  for Drug  Evaluation  and Research 
Division of Dermatology and Dentistry 
5901- B Ammendale Road  
Beltsville,  MD 20705 -1266 
 
CDER- only Biologic  INDs:  
 
Food  and Drug  Administration 
Center for Drug Evaluation and Research 
Therapeutic  Biologic  Products  Document  Room 
5901- B Ammendale Road  
Beltsville,  MD 20705- 1266 
 
CBER  INDs:  
 
Office of xxxx 
Center  for Biologics  Evaluation  and Research 
Food and Drug Administration  
Suite  200N  1401 Rockville Pike 
Rockville, MD 20852- 1448 
 
 
13.2.3  Reporting of SAE to Pfizer,  Inc 
 
 
Institution  will send  Pfizer,  Inc copies  of any and all  serious adverse event  reports 
filed with the FDA or other  applicable regulatory  authorities,  as well as copies  of 
any correspondence with the FDA or other applicable regulatory authorities, 
regarding any and all serious adverse events, irrespective of association or 
relatedness  with the Study  Drug(s) in the course  of the Clinical  Trial,  , at minimum 
once per year.  The Pfizer US drug safety department may request data more 
frequently from the Investigator to support  safety reporting. Serious adverse 
event reports are faxed to 1- 866-997-8322. Contact information for the Pfizer US 
drug safety team is subject to change. For safety reporting questions, please contact Pfizer US safety mailbox contact at SAEFaxmailbox@Pfizer.com.  
 
All SAEs  that occur  will be  promptly reported to the IRB  and medical  monitor for 
the study. SAEs will be reported in accordance with FDA form MedWatch 
3500A  associated with the study  investigator’s  IND. These IND submissions are 
Expedited Safety Reports (7- day or 15- day reports) as defined by the Code of 
Federal  Regulations  21 CFR 312.32(c).  An Expedited Safety  Report  is required  
Protocol  #20-07022368  
Version  Date  5/10/24   
34   
for serious adverse events that are deemed both unexpected and related to the 
investigative  drug.  The protocol  may define that this attribution  can include  events 
considered “possibly related”, and the IND Sponsor -investigator should align with 
their study protocol in this regard. Serious adverse events that do not fit these 
criteri a should still be described in the IND’s  Annual  Report.  All MedWatch 3500A 
forms should be submitted to Biohaven as defined above. These documents are 
critical to updating the comprehensive safety information in our Investigator 
Brochure, which is reviewed and updated at least annually.  
 
 
13.3 AE/SAE  Follow  Up 
 
All SAEs and AEs reported during this study will be followed until resolution or until the 
investigator  confirms  that the AE/SAE  has stabilized  and no more  follow -up is required.  
 
13.4 Time  Period  and Frequency  for Event  Assessment  and Follow  Up 
 
The occurrence of an adverse event (AE) or serious  adverse  event (SAE) may come  to 
the attention of study personnel during study visits and interviews of a study participant 
presenting for medical care, or upon review by a study monitor.  
 
All AEs including local and systemic reactions not meeting the criteria for SAEs will be captured  on the appropriate case  report  form (CRF).  Information  to be collected  includes 
event description, time of onset, clinician’s assessment of severity, relationship to study 
product (assessed only by those with the training and authority  to make  a diagnosis), 
and time of resolution/stabilization of the event.  All AEs occurring  while  on study  must  be 
documented appropriately regardless of  relationship.  All AEs will be followed  to 
adequate resolution.  
 
Any medical condition that is present at the time that the participant is screened will be 
considered as baseline and not reported as an AE. However, if the study participant’s condition  deteriorates  at any time during the study, it will be  recorded as an AE.  
 
Changes in the severity of an AE will be documented to allow an assessment of the 
duration of the event at each level of severity to be performed. AEs characterized as 
intermittent require documentation of onset and duration of each episode.  
 
Dr. Granstein  or other  study  key persons  will record  all reportable events  with start dates 
occurring any time after informed consent  is obtained until 7 (for non-serious  AEs)  or 30 
days  (for SAEs)  after the last day of study  participation.  At each study  visit, the 
investigator will  inquire about the occurrence of AE/SAEs since  the last visit. Events will 
be followed for outcome information until resolution or stabilization.]  
 
14. Unanticipated Problems Involving 
Risks to Subjects or Others  
 
14.1 Definition of Unanticipated Problems Involving Risks to Subjects 
or Others (UPIRTSO)  
Protocol  #20-07022368  
Version  Date  5/10/24   
35   
The Office for Human Research Protections (OHRP) considers unanticipated problems 
involving risks to participants or others to include, in general, any incident, experience, or 
outcome that meets all of the following criteria:  
 
 
• Unexpected in terms  of nature,  severity,  or frequency  given  (a) the research procedures 
that are described in the protocol -related documents, such as the Institutional Review 
Board (IRB) -approved research protocol and informed consent document; and (b) the 
characteristics of the participant population being studied;  
• Related or possibly related to participation in the research (“possibly related” means there 
is a reasonable possibility that the incident, experience, or outcome may have been 
caused by the procedures involved in the research); and  
• Suggests that the research places participants or others  at a greater risk  of harm 
(including physical,  psychological,  economic,  or social  harm)  than was previously  known 
or recognized.  
 
14.1.2  Unanticipated  Problem Reporting 
 
The investigator  will report  unanticipated problems  (UPIRTSOs)  to the reviewing 
Institutional Review Board (IRB) and to the lead principal investigator (PI). The 
UPIRTSO report will include the following information:  
 
• Protocol  identifying information:  protocol  title and number,  PI’s name,  and the 
IRB project number;  
• A detailed  description of the event,  incident,  experience,  or outcome;  
• An explanation  of the basis  for determining that the event,  incident,  experience, 
or outcome represents an UPIRTSO;  
• A description of any changes  to the protocol  or other  corrective  actions  that have 
been taken or are proposed in response to the UPIRTSO.  
 
To satisfy the requirement  for prompt  reporting,  UPIRTSOs  will be reported using  the 
following timeline:  
 
• UPIRTSOs  that are serious  adverse events  (SAEs)  will be reported to the IRB 
and to the DCC/study sponsor within 24 hours of the investigator becoming 
aware of the event.  
• Any other  UPIRTSO  will be reported to the IRB and to the DCC/study  sponsor 
within 7 days of the investigator becoming aware of the problem.  
• All UPs should be reported to appropriate institutional officials (as required by an 
institution’s written reporting procedures), the supporting agency head (or 
designee), Food and Drug Administration (FDA), and the Office for Human 
Research Protections  (OHRP)  within  <insert  timeline  in accordance with policy> 
of the  IRB’s receipt of the report of the problem  from the investigator.] ????? 
 
15. Data  and Safety  Monitoring Plan  (DSMP)  
 
After  discussion with representatives  of the Weill  Cornell  Data  and Safety  Monitoring Board,  at 
their recommendation we have decided to proceed with an Independent  Medical Monitor.  For a 
study of the relatively short duration of subject participation as in our proposal and the known 
safety of the drug being investigated, this appeared to be the best choice.
Protocol  #20-07022368  
Version  Date  5/10/24   
36   
 
Events  that will be captured  and submitted  to the Monitor  are: 
1. Accidental  injuries  
2. Events  related to trial procedures  
3. Reasons  for any unfavorable and unplanned change  in medication.  
4. Clinically  significant  worsening  of pre- existing  conditions.  
5. Reasons  for admission to hospital  or surgical  procedures  unless  these admissions  or 
procedures were planned before the subject consented to trial participation.  
6. Adverse events  anticipated based on the pharmacological  effects  of rimegepant.  
7. Any laboratory  abnormality  felt to be clinically  significant  by the investigator.  
Serious  adverse events  are defined as: 
1. An event  resulting  in death 
2. An event  that is life-threatening  
3. An event  that requires  inpatient  hospitalization other  than planned hospitalizations  that 
do not fulfill the criteria for being a serious adverse event.  
4. An event  that results  in persistent  or significant  disability  or incapacity.  
5. A medically  important event that may  not be immediately  life-threatening or result in 
death or hospitalization  but may jeopardize the subject  or require  intervention to prevent 
one of the outcomes listed above.  
The following  adverse  events  will result  in terminating protocol  treatment:  
1. Anaphylactic  reaction or other  systemic reaction to rimegepant.  
2. Any adverse  reaction that in the opinion  of the investigator  contraindicates  further 
dosing.  
3. Diagnosis  of a malignancy  during the trial excluding  carcinoma  in situ of the cervix or 
localized squamous or basal cell carcinoma of the skin.  
4. Evidence  of pregnancy.  
5. Any infection that is opportunistic  whose nature or course  may suggest  an 
immunocompromised status.  
6. Significant  abnormalities including an ALT or  AST value  more than 3 times the upper limit  
of normal,  total bilirubin more  than 2 times  the upper  limit of normal  unless related to 
Gilbert Syndrome.  
Adverse events  that are not accurately  reflected  in the Informed  Consent  Form  or the package 
insert  of the medication that is related or possibly  related to the pharmacological  intervention 
and that has greater risk of harm to the subject is present than was previously known or 
recognized will be reported to the  Independent Medical Monitor within 7 days.  Severe adverse 
events will be reported to the Medical Monitor as soon as possible and definitely within 3 days.  
Additionally, quarterly  reports  on all subjects  experiencing adverse events will  be submitted  to 
the monitor throughout the study.  
 
There are no defined rules  for stopping the study  prior to completion  by all of the enrolled 
subjects. Given the known safety data of the investigational agent. This seems quite 
reasonable.  
The Independent  Medical  Monitor’s  comments  will be provided to the IRB at the time of each 
continuing review.  
Protocol  #20-07022368  
Version  Date  5/10/24   
37   
16. References  
 
1. Rajguru JP, Maya  D, Kumar  D, Suri P, Bhardwaj  S, Patel  ND. Update on psoriasis:  A review. 
J Family Med Prim Care. 2020, 9:20- 24. 
 
2. Takeshita J, Grewal S, Langan SM, Mehta NN, Ogdie A, Van Voorhees AS, Gelfand JM. 
Psoriasis  and comorbid  diseases:  Implications  for management.  J Am Acad  Dermatol.  2017, 
76:393- 403. 
 
3. Greb  JE, Goldminz  AM, Elder  JT, Lebwohl MG,  Gladman  DD, Wu JJ, Mehta NN, Finlay  AY, 
Gottlieb AB. Psoriasis. Nat Rev Dis Primers. 2016, 24;2:16082.  
 
4. Kaushik  SB, Lebwohl  MG. Review  of safety  and efficacy  of approved systemic psoriasis 
therapies. Int J Dermatol. 2019, 58:649- 658. 
 
5. Rácz  E, Prens  EP. Phototherapy  of Psoriasis,  a Chronic  Inflammatory  Skin Disease. 
Adv Exp Med Biol. 2017, 996:287- 294. 
 
6. Farber  EM, Lanigan SW, Boer  J. The role of cutaneous  sensory nerves  in the maintenance  of 
psoriasis. Int J Dermatol. 1990, 29:418- 20. 
 
7. Zhu TH,  Nakamura  M, Farahnik  B, Abrouk  M, Lee K, Singh  R, Gevorgyan A, Koo J, Bhutani  
T. The role of the nervous system in the pathophysiology of psoriasis: A review of cases of 
psoriasis remission or improvement following denervation injury. Am J Clin Dermatol. 2016, 
17:257- 63. 
 
8. HH Perlman. Remission of psoriasis vulgaris from the use of nerve- blocking agents. Arch 
Dermatol. 1972,105:128- 9. 
 
9. Aschenbeck KA, Hordinsky  MK, Kennedy  WR, Wendelschafer -Crabb G, Ericson  ME, Kavand 
S, Bertin A, Dykstra DD, Panoutsopoulou IG. Neuromodulatory treatment of recalcitrant plaque 
psoriasis with onabotulinumtoxin A. J Am Acad Dermatol. 2018, 79:1156- 1159.  
 
10. Ostrowski SM, Belkadi A, Loyd CM, Diaconu D, Ward NL. Cutaneous denervation of 
psoriasiform  mouse  skin improves  acanthosis  and inflammation in a sensory  neuropeptide-  
dependent manner. J Invest Dermatol. 2011, 131:1530- 8. 
 
11. EM Baerveldt, AJ Onderdijk, C Wohn, M Kant, EF Florencia, IJ  Hekking -Weijma,  ET Walbeehm,  
WR Swindell,  JE Gudjonsson,  EP Prens.  Denervation impairs  clinical  development  of 
imiquimodinduced psoriasiform  skin inflammation in mice.  J Invest Dermatol. 2012,132(Suppl 2s), 
S17 (abstract).  
 
12. Reich  A, Orda  A, Wiśnicka B, Szepietowski  JC. Plasma  concentration of selected 
neuropeptides in patients suffering from  psoriasis. Exp Dermatol. 2007, 16:421- 8. 
 
13. He Y, Ding G, Wang X, Zhu T, Fan S. Calcitonin gene- related peptide in Langerhans cells in 
psoriatic plaque lesions. Chin Med J (Engl). 2000, 113:747- 51. 
Protocol  #20-07022368  
Version  Date  5/10/24   
38   
14. Riol-Blanco L, Ordovas -Montanes  J, Perro  M, Naval  E, Thiriot  A, Alvarez  D, Paust  S, Wood 
JN, von  Andrian UH. Nociceptive sensory neurons drive interleukin- 23-mediated psoriasiform 
skin inflammation. Nature. 2014, 510:157- 61. 
 
15. Kashem  SW, Riedl  MS, Yao C, Honda CN, Vulchanova  L, Kaplan  DH. Nociceptive  Sensory 
Fibers Drive Interleukin- 23 Production from CD301b+  Dermal Dendritic  Cells  and Drive 
Protective Cutaneous Immunity. Immunity. 2015, 43:515- 26. 
 
16. Ding W, Stohl LL, Xu L, Zhou XK, Manni M, Wagner JA, Granstein RD. Calcitonin Gene - 
Related Peptide -Exposed Endothelial  Cells  Bias Antigen Presentation to CD4+  T Cells  toward a 
Th17 Response. J Immunol. 2016,196:2181- 94. 